COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients

First posted Sep 10, 2021

Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack

1,601 participants · First posted Mar 11, 2020

Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.

755 participants · First posted Jan 6, 2020

DSR-130787

FXIa Inhibitor(Sino-American Shanghai Squibb Pharmaceuticals Ltd.)

IXIA-10

Spatz FGIA, Inc.

United States

Axia Medical Solutions, LLC

United States

Bayer's Asundexian Meets Primary Endpoints in Phase III OCEANIC-STROKE Trial for Secondary Stroke Prevention

Cadrenal Therapeutics Acquires eXIthera's Factor XIa Inhibitor Portfolio in $15M Deal

OCEANIC-STROKE Phase 3 Trial Advances Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention